Last reviewed · How we verify

Split-dose low-volume PEG

Kyunghee University Medical Center · FDA-approved active Small molecule

Split-dose low-volume polyethylene glycol (PEG) solution reduces bowel preparation volume while maintaining efficacy by dividing the dose into smaller administrations.

Split-dose low-volume polyethylene glycol (PEG) solution reduces bowel preparation volume while maintaining efficacy by dividing the dose into smaller administrations. Used for Bowel preparation prior to colonoscopy.

At a glance

Generic nameSplit-dose low-volume PEG
SponsorKyunghee University Medical Center
Drug classOsmotic laxative / bowel preparation agent
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

This formulation uses polyethylene glycol as an osmotic laxative agent in a lower total volume compared to standard PEG preparations, administered in split doses (typically evening before and morning of procedure) to improve tolerability and patient compliance. The split-dosing strategy allows for better absorption and efficacy while reducing the gastrointestinal burden of consuming large fluid volumes in a single sitting.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: